GA-002

**GA-002** is a preclinical bicistronic adeno-associated virus gene therapy originally described by Genosera and Solve GNE for **GNE myopathy**, also known as hereditary inclusion body myopathy. The vector is intended to deliver a functional copy of the **GNE** gene together with an unspecified muscle growth or regenerative-factor gene. This dual-gene strategy is designed both to correct the underlying GNE deficiency and to promote restoration of muscle mass and strength in already affected muscle. The program originated from dual-gene AAV research at Nationwide Children’s Hospital. ([biospace.com](https://www.biospace.com/solve-gne-and-genosera-sign-agreement-to-develop-a-novel-bicistronic-aav-gene-therapy-targeting-hibm))

Other names

GA 002GA002GA-002